Show simple item record

dc.contributor.authorVezzoli, Elena
dc.contributor.authorCaron, Ilaria
dc.contributor.authorTalpo, Francesca
dc.contributor.authorBesusso, Dario
dc.contributor.authorConforti, Paola
dc.contributor.authorBattaglia, Elisa
dc.contributor.authorSogne, Elisa
dc.contributor.authorFalqui, Andrea
dc.contributor.authorPetricca, Lara
dc.contributor.authorVerani, Margherita
dc.contributor.authorMartufi, Paola
dc.contributor.authorCaricasole, Andrea
dc.contributor.authorBresciani, Alberto
dc.contributor.authorCecchetti, Ottavia
dc.contributor.authorRivetti di Val Cervo, Pia
dc.contributor.authorSancini, Giulio
dc.contributor.authorRiess, Olaf
dc.contributor.authorNguyen, Hoa
dc.contributor.authorSeipold, Lisa
dc.contributor.authorSaftig, Paul
dc.contributor.authorBiella, Gerardo
dc.contributor.authorCattaneo, Elena
dc.contributor.authorZuccato, Chiara
dc.date.accessioned2019-05-13T11:37:19Z
dc.date.available2019-05-13T11:37:19Z
dc.date.issued2019-05-06
dc.identifier.citationVezzoli E, Caron I, Talpo F, Besusso D, Conforti P, et al. (2019) Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington’s disease. Journal of Clinical Investigation. Available: http://dx.doi.org/10.1172/jci120616.
dc.identifier.issn0021-9738
dc.identifier.issn1558-8238
dc.identifier.doi10.1172/jci120616
dc.identifier.urihttp://hdl.handle.net/10754/652854
dc.description.abstractA disintegrine and metalloproteinase 10 (ADAM10) is implicated in synaptic function through its interaction with postsynaptic receptors and adhesion molecules. Here, we report that levels of active ADAM10 are increased in Huntington's disease (HD) mouse cortices and striata and in human postmortem caudate. We show that, in the presence of polyglutamine-expanded (polyQ-expanded) huntingtin (HTT), ADAM10 accumulates at the postsynaptic densities (PSDs) and causes excessive cleavage of the synaptic protein N-cadherin (N-CAD). This aberrant phenotype is also detected in neurons from HD patients where it can be reverted by selective silencing of mutant HTT. Consistently, ex vivo delivery of an ADAM10 synthetic inhibitor reduces N-CAD proteolysis and corrects electrophysiological alterations in striatal medium-sized spiny neurons (MSNs) of 2 HD mouse models. Moreover, we show that heterozygous conditional deletion of ADAM10 or delivery of a competitive TAT-Pro-ADAM10709-729 peptide in R6/2 mice prevents N-CAD proteolysis and ameliorates cognitive deficits in the mice. Reduction in synapse loss was also found in R6/2 mice conditionally deleted for ADAM10. Taken together, these results point to a detrimental role of hyperactive ADAM10 at the HD synapse and provide preclinical evidence of the therapeutic potential of ADAM10 inhibition in HD.
dc.description.sponsorshipThis study was supported by grants from Telethon (GGP13053) to CZ and from the Ministero dell’Istruzione, dell’Università e della Ricerca Scientifica, Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale to CZ and GS (20128XWKTX); from Neuromics (305121), ModelPolyQ (JPCOFUND-643417), and CircProt (JPCOFUND-643417) to EC; from the Deutsche Forschungsgemeinschaft (DFG-SFB877-A3) to PS; from the Interuniversity Attraction Poles (IAP-P5) and the Breuer Foundation Research Award to PS and ES; and from KAUST baseline funding to AF. AB, AC, LP, MV, PM, and OC were supported by CNCCS Scarl. We acknowledge the CHDI Foundation for zQ175 mice and NOLIMITS, an advanced imaging facility established by the Università degli Studi di Milano. We thank the Italian HD patients and families for their closeness and trust.
dc.publisherAmerican Society for Clinical Investigation
dc.relation.urlhttps://www.jci.org/articles/view/120616
dc.rightsArchived with thanks to Journal of Clinical Investigation
dc.titleInhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington’s disease
dc.typeArticle
dc.contributor.departmentBiological and Environmental Sciences and Engineering (BESE) Division
dc.contributor.departmentBioscience Program
dc.identifier.journalJournal of Clinical Investigation
dc.eprint.versionPublisher's Version/PDF
dc.contributor.institutionDepartment of Biosciences, University of Milan, Milan, Italy.
dc.contributor.institutionDepartment of Biology and Biotechnologies, University of Pavia, Pavia, Italy.
dc.contributor.institutionIRBM Science Park SpA, Pomezia, Italy.
dc.contributor.institutionSchool of Medicine and Surgery, Nanomedicine Center, Neuroscience Center, University of Milano-Bicocca, Monza, Italy.
dc.contributor.institutionInstitute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany.
dc.contributor.institutionInstitute of Biochemistry, Christian Albrechts University of Kiel, Kiel, Germany.
kaust.personSogne, Elisa
kaust.personFalqui, Andrea
refterms.dateFOA2019-05-13T13:14:15Z
dc.date.published-online2019-05-06
dc.date.published-print2019-05-06


Files in this item

Thumbnail
Name:
120616.1-20190503181339-covered-253bed37ca4c1ab43d105aefdf7b5536.pdf
Size:
5.966Mb
Format:
PDF
Description:
Published version
Thumbnail
Name:
JCI120616.sd.pdf
Size:
745.3Kb
Format:
PDF
Description:
Supplemental files

This item appears in the following Collection(s)

Show simple item record